You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

TASMAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tasmar patents expire, and when can generic versions of Tasmar launch?

Tasmar is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in TASMAR is tolcapone. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tolcapone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tasmar

A generic version of TASMAR was approved as tolcapone by PAR PHARM INC on March 26th, 2015.

  Try a Trial

Drug patent expirations by year for TASMAR
Drug Prices for TASMAR

See drug prices for TASMAR

Recent Clinical Trials for TASMAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ChicagoPhase 2
University of Colorado, DenverPhase 2
Corino Therapeutics, Inc.Early Phase 1

See all TASMAR clinical trials

Pharmacology for TASMAR
Anatomical Therapeutic Chemical (ATC) Classes for TASMAR

US Patents and Regulatory Information for TASMAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch TASMAR tolcapone TABLET;ORAL 020697-001 Jan 29, 1998 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bausch TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TASMAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch TASMAR tolcapone TABLET;ORAL 020697-001 Jan 29, 1998 ⤷  Try a Trial ⤷  Try a Trial
Bausch TASMAR tolcapone TABLET;ORAL 020697-001 Jan 29, 1998 ⤷  Try a Trial ⤷  Try a Trial
Bausch TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 ⤷  Try a Trial ⤷  Try a Trial
Bausch TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for TASMAR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Viatris Healthcare Limited Tasmar tolcapone EMEA/H/C/000132
Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.
Authorised no no no 1997-08-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for TASMAR

See the table below for patents covering TASMAR around the world.

Country Patent Number Title Estimated Expiration
South Korea 930001054 ⤷  Try a Trial
Luxembourg 90219 ⤷  Try a Trial
Ireland 61316 3,5-disubstituted pyrocatechol derivatives ⤷  Try a Trial
Czechoslovakia 9104022 ⤷  Try a Trial
Ireland 870609 ⤷  Try a Trial
Netherlands 970041 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TASMAR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0237929 C970041 Netherlands ⤷  Try a Trial PRODUCT NAME: TOLCAPON; REGISTRATION NO/DATE: EU/1/97/044/001-6 19970827
0237929 97C0112 Belgium ⤷  Try a Trial PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 19970827
0237929 68/1997 Austria ⤷  Try a Trial PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827
0237929 SPC/GB97/088 United Kingdom ⤷  Try a Trial PRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.